Welcome to our dedicated page for Organogenesis Holdings news (Ticker: ORGO), a resource for investors and traders seeking the latest updates and insights on Organogenesis Holdings stock.
Organogenesis Holdings Inc. (Nasdaq: ORGO) is a pioneering company in the field of regenerative medicine. Headquartered in Canton, Massachusetts, Organogenesis offers a diverse portfolio of bioactive and acellular biomaterial products, primarily targeting the Advanced Wound Care and Surgical & Sports Medicine markets. The company's innovative solutions cater to a wide range of patients with repair and regenerative needs.
The company's core products include PuraPly Antimicrobial, Affinity, NuShield, Apligraf, and Dermagraft, which are designed to improve patient outcomes while reducing overall healthcare costs. Organogenesis is recognized for its advancements in both orthopedics and spine treatments, reflecting its commitment to addressing unmet medical needs through cutting-edge research and development.
In recent news, Organogenesis has reported significant milestones and achievements. The company announced that its Phase 3 randomized control trial evaluating ReNu, a cryopreserved amniotic suspension allograft for knee osteoarthritis (OA), met its primary endpoint, demonstrating a significant reduction in knee OA pain. This achievement is poised to introduce new non-surgical treatment options for OA patients, potentially opening a significant market opportunity for Organogenesis.
The company has also faced challenges. Its third-quarter revenue was impacted by local coverage determination (LCD) issues, yet it managed to deliver substantial improvements in operating profitability and adjusted EBITDA. Organogenesis continues to build momentum with commercial support programs aimed at enhancing customer relationships and regaining lost accounts.
Financially, the company reported a net revenue of $99.7 million in the fourth quarter of 2023, reflecting a decrease from the previous year. Despite these hurdles, Organogenesis remains financially robust with $104.3 million in cash and equivalents as of December 2023. Its operating expenses have been carefully managed, showcasing a reduction in selling, general, and administrative expenses.
Looking ahead, Organogenesis has set optimistic projections for 2024, with anticipated revenue growth driven by new product launches and the continued demonstration of value to customers. The company is also planning to further engage with regulatory bodies to secure approvals and expand the clinical indications of its products.
Overall, Organogenesis Holdings Inc. stands out for its commitment to innovation, patient care, and financial stability, making it a significant player in the regenerative medicine landscape. For more information, visit their official website.
Organogenesis Holdings (Nasdaq: ORGO) will participate in the Credit Suisse 30th Annual Healthcare Conference from November 8-11, 2021. A fireside chat featuring company management is scheduled for November 11 at 9:40 a.m. ET. The event will be held virtually, and a live audio webcast will be accessible via the ‘Upcoming Events’ section on Organogenesis’s Investor Relations page. An archived version of the webcast will be available for 30 days post-conference.
Organogenesis specializes in regenerative medicine, offering bioactive products for advanced wound care and surgical markets.
Organogenesis Holdings Inc. (Nasdaq: ORGO) will showcase advanced wound care research at the 2021 Symposium on Advanced Wound Care Fall Conference in Las Vegas from October 29-31. Key presentations include a lunch symposium discussing in vivo data on PuraPly technology and a session on dermal substitutes post-Mohs surgery. The company also highlights its Adjustable Curette, aimed at enhancing wound debridement. Organogenesis, a leader in regenerative medicine, focuses on innovative solutions for advanced wound care and surgical applications.
Organogenesis Holdings Inc. (Nasdaq: ORGO) announced that it will release its third-quarter financial results on November 9, 2021, after the market closes. The company will hold a conference call at 5:00 p.m. ET the same day to discuss these results and provide updates on corporate developments. Participation can be done via a dedicated phone line and a live webcast will be available on their investor relations website. Organogenesis specializes in regenerative medicine, focusing on advanced wound care and surgical biologics.
Organogenesis Holdings has announced their participation in two significant investor conferences. The management will engage in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on September 14th at 1:15 p.m. ET. Additionally, they will present at the Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit on September 20th at 3:45 p.m. ET. Live audio webcasts will be available on their website, with replays accessible for 30 days post-conference.
Organogenesis Holdings Inc. (Nasdaq: ORGO) has partnered with Net Health to become the first to utilize Net Health's CTP Connections Module, enabling the electronic submission of insurance benefits verification forms. This initiative aims to enhance efficiency for hospital and outpatient wound care providers in verifying benefits for Organogenesis's cell and tissue-based products. The service is provided at no extra cost to Net Health Wound Care users, minimizing administrative errors and speeding up responses from payors, ultimately improving patient access to critical products.
Organogenesis Holdings Inc. (Nasdaq: ORGO) reported robust financial results for Q2 2021, with net revenue reaching $123.2 million, a 79% increase year-over-year. Key drivers included Advanced Wound Care products at $111.4 million (up 87%) and Surgical & Sports Medicine at $11.8 million (up 27%). The company achieved a net income of $20.7 million, reversing a loss of $5.2 million in Q2 2020. Adjusted EBITDA increased to $25.1 million, or 20.4% of net revenue, compared to $0.3 million in the prior year.
Organogenesis Holdings Inc. (Nasdaq: ORGO) has announced a new credit agreement with Silicon Valley Bank, introducing a $200 million credit facility. This includes a $75 million term loan and a $125 million revolving credit line, aimed at general corporate purposes and repaying an existing $100 million facility. Senior VP Henry Hagopian emphasized that this agreement will lower borrowing costs and support long-term growth. The partnership reflects the bank's commitment to the company’s innovation in advanced healing solutions.
Organogenesis Holdings Inc. (Nasdaq: ORGO) plans to release its second-quarter fiscal year 2021 financial results on August 9, after market close. The management will host a conference call at 5:00 p.m. ET on the same day to discuss the results, followed by a Q&A session. Interested participants can join the call via phone or through a live webcast available on the company's investor relations website. A replay will be accessible for two weeks post-call. Organogenesis specializes in regenerative medicine focused on advanced wound care and surgical solutions.
Crocs Inc. (CROX) is set to replace Cantel Medical Corp. (CMD) in the S&P MidCap 400, effective June 2, 2021. Concurrently, Organogenesis Holdings Inc. (ORGO) will take Crocs' place in the S&P SmallCap 600. This change is part of an acquisition by STERIS plc of Cantel Medical, which is anticipated to conclude soon pending final conditions. This move reflects Crocs' growing presence in the market and the dynamics of index composition.
FAQ
What is the current stock price of Organogenesis Holdings (ORGO)?
What is the market cap of Organogenesis Holdings (ORGO)?
What is Organogenesis Holdings Inc.?
Where is Organogenesis Holdings Inc. headquartered?
What are some of the core products of Organogenesis?
What recent achievement has Organogenesis announced?
How did Organogenesis perform financially in the fourth quarter of 2023?
What are the future prospects for Organogenesis?
What markets does Organogenesis target?
What is the significance of ReNu in Organogenesis's portfolio?
How does Organogenesis contribute to healthcare cost reduction?
Where can more information about Organogenesis be found?
